All patients in a Phase 1/2 trial examining two doses of AP01, an inhaled version of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), are switching to the higher dose based on the recommendation of a data safety monitoring board (DSMB). Avalyn Pharma, AP01’s developer, reported that…
Trial to Test Higher Dose of Inhaled Pirfenidone in All Participants
A Phase 2 study of NP-120 (ifenprodil) for chronic cough associated with idiopathic pulmonary fibrosis (IPF) has reached 25% of its enrollment target, Algernon Pharmaceuticals, the therapy’s developer, has announced. “I am very pleased to report that we have reached 25% enrollment in the study,” Christopher J. Moreau, CEO…
Oct. 10 was World Mental Health Day. I am a bit late to the party, but with a twice-monthly publishing schedule, this is my first opportunity to share a column inspired by Mental Health Day. In previous columns, I have discussed my mental health struggles and how I use…
A protein-coding gene called Spred2 may contribute to pulmonary fibrosis (PF) development, potentially representing a new therapeutic target, according to the results of a new study. Titled “Spred2-deficiency enhances the proliferation of lung epithelial cells and alleviates pulmonary fibrosis induced by bleomycin,” the study was…
I began hearing the term “toxic positivity” this year, and the pandemic has illuminated the term’s meaning for me. According to The Psychology Group in Fort Lauderdale, Florida, toxic positivity refers to “the excessive and ineffective overgeneralization of a happy, optimistic state across all situations.” Since the beginning of…
Treatment with inhalable bone morphogenic protein 4 (BMP4) — a soluble signaling molecule involved in the regulation of cellular identity — restored lung regeneration and improved lung function in a mouse model of idiopathic pulmonary fibrosis (IPF). The data showed that scar-forming cells in IPF lungs suppress BMP signaling…
People with idiopathic pulmonary fibrosis (IPF) who have three or more abnormally large lymph nodes in the area of the lungs and heart — a condition known as mediastinal lymph node enlargement (LNE) — have an increased risk of mortality and faster disease progression, a study found. The…
Esbriet (pirfenidone), an approved treatment for idiopathic pulmonary fibrosis (IPF), seems to be safe in IPF patients who also have non‐small cell lung cancer (NSCLC) when combined with cancer therapy. The finding is detailed in the study, “Safety and effectiveness of pirfenidone combined with carboplatin‐based chemotherapy in patients…
Continuous hemoperfusion, a technique used to filter toxins from blood, was effective in improving the survival rates of people with acute poisoning due to paraquat, an herbicide used in lawn care. The technique may have implications for the treatment of patients with paraquat-induced pulmonary fibrosis (PF), a…
Last week was the first of an eight-week Pulmonary Wellness Foundation (PWF) peer support group. I have been collaborating with the PWF since January to build this unique peer support group for patients with pulmonary fibrosis. It was surreal to finally launch it. Though I’ve always advocated for the…
